Most companies that are getting ready to apply for approval do not do further studies until post approval . Its risky in so many ways.They already have enough data in my opinion to get approval sometime next year . The only thing another study adds is more risk . You can get Saes even though they have not seen them up until this point.More data can add more questions , they have plenty .It would be better for them to just get bought out . But if you look at their market cap and the potential first 2 years of sales no one will pay to much of a premium over 40$. The other agents will be here in 2 to 3 years.
Any significance to the fact that this trial is using Pegasys and not both Pegalyted Interferon's? I noticed their VX-222 trial also lists just Pegasys.
News 
Market Data 
Discover 
AI
